Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 16/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441201 | 0.80 | NR3C1 (0.46) | NR3C1PGR | |
| SCHEMBL9943362 | 0.72 | NR3C1 (0.62) | NR3C1PGR | |
| SCHEMBL9943361 | 0.72 | NR3C1 (0.62) | NR3C1PGR | |
| SCHEMBL835586 | 0.71 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL412277 | 0.71 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL12101194 | 0.71 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL835568 | 0.70 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL12253495 | 0.68 | SLC34A1 (0.58) | PLK1 | |
| SCHEMBL5136736 | 0.68 | SLC34A1 (0.42) | PLK1NR3C1RORC | |
| SCHEMBL27834342 | 0.66 | KHK (0.57) | RARGRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | PLK1 2654/4885NR3C1 1/4885PGR 263/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | PLK1 2652/4885NR3C1 1/4885PGR 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.